Federal Bill of the Month – April 2026: H.R. 8293 – Abolish the CMMI Act

Introduced by Rep. Aaron Bean (R-Fl.), H.R. 8293—the Abolish the CMMI Act—would be a welcome step toward fiscal responsibility and consumer choice in healthcare. According to the Government Accountability Office (GAO), the Center for Medicare and Medicaid Innovation (CMMI) has cost taxpayers $11.4 billion since its inception in 2010. While the agency was created to test and implement innovative healthcare payment and service delivery models, it has abysmally failed. In the last decade, CMMI has launched over 50 model tests. Of these model tests, only six have generated statistically significant savings for Medicare and, by extension, taxpayers. 

CMMI was originally intended for small-scale healthcare payment reforms but has evolved into a tool for implementing national healthcare policies without Congressional approval. And now, it is being used to implement onerous price controls on medications. In December, the Centers for Medicare & Medicaid Services (CMS) announced a pair of new mandatory payment models that bear a troubling resemblance to President Trump’s Most Favored Nation (MFN) approach to price-fixing drugs.

Echoing the President’s Executive Order, the Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) models tie the prices of drugs payable under Medicare Parts B and D to those in foreign countries with socialized healthcare systems. Using CMMI to “test” models certain to cause drug shortages is simply a terrible use of taxpayer dollars.

Rep. Bean’s bill would spare taxpayers from reckless federal spending—while ensuring that consumers are not subject to heavy-handed price controls. For these reasons, the Taxpayers Protection Alliance is pleased to make H.R. 8293 its Federal Bill of the Month for April 2026.